Revive Therapeutics (CSE: RVV) announced after the bell today that it has officially filed its investigational new drug (IND) application to the US FDA for its Phase 3 confirmatory study. The study will focus on utilizing bucillamine as a potential treatment for COVID-19 and other infectious diseases. Once the application is accepted, Revive will conduct … Continue reading Revive Files IND Application With FDA For Phase 3 Clinical Study For COVID-19 Treatment